{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:43:29Z","timestamp":1770079409671,"version":"3.49.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":457,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Therapy of acute hepatitis C (AHC) has not yet been standardized and several issues are still unresolved. This open, randomized, multicenter trial aimed to assess the efficacy and safety of a 24-week course of pegylated IFN (Peg-IFN) alpha-2b versus a 12-week course of Peg-IFN alpha-2b alone or with ribavirin (RBV) in AHC patients. One hundred and thirty HCV acutely infected patients who did not spontaneously resolve by week 12 after onset were consecutively enrolled and randomized to receive Peg-IFN alpha-2b monotherapy (1.5 \u03bcg\/kg\/week) for 24 or 12 weeks (arm 1, n = 44 and arm 2, n = 43, respectively) or in combination with RBV (10.6 mg\/kg\/day) for 12 weeks (arm 3, n = 43). The primary endpoint was undetectable HCV RNA at 6-month posttreatment follow-up (sustained virological response; SVR). All patients were followed for 48 weeks after therapy cessation. HCV RNA levels were determined by real-time polymerase chain reaction (limit of detection: 15 IU\/mL) at the central laboratory at baseline, week 4, end of treatment, and 6 and 12 months posttreatment. Using an intent-to-treat analysis, overall SVR rate was 71.5%. In particular, an SVR was achieved in 31 of 44 (70.5%), 31 of 43 (72.1%), and 31 of 43 (72.1%) patients in arms 1, 2, and 3, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.898). Sixteen patients (12.3%) prematurely discontinued therapy or were lost to follow-up; thus, sustained response rates with per-protocol analysis were 81.6%, 81.6%, and 81.6% for patients in arms 1, 2, and 3 respectively. With multivariate analysis, virologic response at week 4 of treatment was an independent predictor of SVR. Peg-IFN alpha-2b was well tolerated. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: Peg-IFN alpha-2b induces a high SVR in chronically evolving AHC patients. Response rates were not influenced by combination therapy or treatment duration. (Hepatology 2014;59:2101-2109)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26991","type":"journal-article","created":{"date-parts":[[2014,1,18]],"date-time":"2014-01-18T04:09:44Z","timestamp":1390018184000},"page":"2101-2109","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":37,"title":["Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin"],"prefix":"10.1097","volume":"59","author":[{"given":"Teresa","family":"Santantonio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelista","family":"Sagnelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Tundo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Babudieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Toti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eligio","family":"Pizzigallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gioacchino","family":"Angarano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20251014","doi-asserted-by":"crossref","first-page":"321331","DOI":"10.1002\/hep.21902","article-title":"Acute hepatitis C virus infection: a chronic problem.","volume":"47","author":"Blackard","year":"2008","journal-title":"Hepatology"},{"key":"R2-11-20251014","doi-asserted-by":"crossref","first-page":"11541159","DOI":"10.1086\/507640","article-title":"Risk factors and outcome among a large patient cohort with communityacquired acute hepatitis C in Italy.","volume":"43","author":"Santantonio","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R3-11-20251014","doi-asserted-by":"crossref","first-page":"625633","DOI":"10.1016\/j.jhep.2008.07.005","article-title":"Acute hepatitis C: current status and remaining challenges.","volume":"49","author":"Santantonio","year":"2008","journal-title":"J Hepatol"},{"key":"R4-11-20251014","doi-asserted-by":"crossref","first-page":"10561062","DOI":"10.1016\/S0168-8278(03)00461-6","article-title":"When and how to treat acute hepatitis C?","volume":"39","author":"Licata","year":"2003","journal-title":"J Hepatol"},{"key":"R6-11-20251014","first-page":"392420","article-title":"EASL Clinical Practice guidelines: management of hepatitis C virus infection.","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"R7-11-20251014","doi-asserted-by":"crossref","first-page":"13351374","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R8-11-20251014","doi-asserted-by":"crossref","first-page":"201207","DOI":"10.1111\/j.1365-2893.2009.01167.x","article-title":"Early treatment improves outcomes in acute hepatitis C virus infection: a metaanalysis.","volume":"17","author":"Corey","year":"2010","journal-title":"J Viral Hepat"},{"key":"R9-11-20251014","doi-asserted-by":"crossref","first-page":"120129","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"R10-11-20251014","doi-asserted-by":"crossref","first-page":"104113","DOI":"10.1016\/S1590-8658(03)00007-0","article-title":"Natural course of acute hepatitis C: a longterm prospective study.","volume":"35","author":"Santantonio","year":"2003","journal-title":"Dig Liver Dis"},{"key":"R11-11-20251014","first-page":"8088","article-title":"Acute hepatitis C: high rate of both spontaneous and treatmentinduced viral clearance.","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"R12-11-20251014","doi-asserted-by":"crossref","first-page":"329333","DOI":"10.1016\/j.jhep.2004.11.021","article-title":"Efficacy of a 24week course of PEGinterferon a2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.","volume":"42","author":"Santantonio","year":"2005","journal-title":"J Hepatol"},{"key":"R13-11-20251014","doi-asserted-by":"crossref","first-page":"250256","DOI":"10.1002\/hep.21043","article-title":"Early monotherapy with pegylated interferon alpha2b for acute hepatitis C infection: the HEPNET acuteHCVII study.","volume":"43","author":"Wiegand","year":"2006","journal-title":"Hepatology"},{"key":"R14-11-20251014","doi-asserted-by":"crossref","first-page":"116121","DOI":"10.1111\/j.1365-2893.2006.00802.x","article-title":"A short course of pegylated interferona in acute HCV hepatitis.","volume":"14","author":"Calleri","year":"2007","journal-title":"J Viral Hepat"},{"key":"R15-11-20251014","doi-asserted-by":"crossref","first-page":"323328","DOI":"10.1016\/j.jhep.2004.11.018","article-title":"Barriers to interferona therapy are higher in intravenous drug users than in other patients with acute hepatitis C.","volume":"42","author":"Broers","year":"2005","journal-title":"J Hepatol"},{"key":"R16-11-20251014","doi-asserted-by":"crossref","first-page":"360363","DOI":"10.1093\/jac\/dki458","article-title":"Dosedependent and genotypeindependent sustained virological response of a 12 week pegylated interferon alpha2b treatment for acute hepatitis C.","volume":"57","author":"De Rosa","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R17-11-20251014","first-page":"497506","article-title":"Early versus delayed treatment of acute hepatitis C: final results of the randomized controlled German HEPNET acute HCVIII Study.","volume":"13","author":"Deterding","year":"2013","journal-title":"Lancet Infect Dis"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26991","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201406000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:54:07Z","timestamp":1760457247000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201406000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26991","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}